Consistent and scalable human iPSC-derived cells for in vitro disease modelling and drug discovery
Kam Dhaliwal and Thomas Moreau discuss how Ó£ÌÒÊÓƵ are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Explore ioCells
Kam Dhaliwal and Thomas Moreau discuss how Ó£ÌÒÊÓƵ are working to solve the problem of restricted access to reliable human cells using next-generation precision reprogramming technology.
Listen to our talk at ELRIG Drug Discovery Digital to learn how Ó£ÌÒÊÓƵ’s opti-ox technology can generate cells with high consistency and functionality at scale from human iPSCs, including those carrying disease-specific mutations, providing high-quality human models for enhanced research outcomes and drug discovery efficiency.